The contribution of resuscitation before admission to hospital, coronary care units, treatment with beta blockers after myocardial infarction, coronary artery bypass surgery, and the treatment of hypertension to the decline in mortality from coronary heart disease in Auckland between 1974 and 1981 was assessed by using data from several population based studies.
Introduction
Explanations for the continuing decline in mortality from coronary heart disease in the United States and several other countries remain populations to measure the relative contributions to the decline. Goldman and Cook,' following Stern,' suggested that 40% of the decline in the United States between 1968 and 1976 was attributable to specific medical interventions.
Mortality from coronary heart disease declined in New Zealand by 20% in the 14 years from 1968,6 and between 1974 and 1981 there was a 16% decline in the sudden death rate in Auckland. 7 In this paper data from several population based studies were used to measure the likely contribution of medical management to the decline in mortality from coronary heart disease in Auckland for the period .
The population of Auckland at the 1981 Census was 829 000, one quarter of the total New Zealand population; the age structure of the Auckland population is similar to that of the total New Zealand population. The following components of medical management were examined: resuscitation before admission to hospital; coronary care units; the use of beta blockers after myocardial infarction; coronary artery bypass surgery; and the pharmacological treatment of hypertension.
Impact of decline in coronary heart disease National mortality data indicate that in 1981 there were 506 fewer deaths from coronary heart disease (International Classification of Diseases (9th revision) codes 410-14) in New Zealand for people aged less than 70 than expected from the 1974 rates; this is equivalent to 126 (100 men, 26 women) fewer deaths from coronary heart disease in this age group in the Auckland region. This estimate is supported by data from two coronary heart disease registers conducted in Auckland in 1974 and 1981 ((715x0 9x0 3x0O025)-(525x0 84x  0 715xO025) ). This is 2% of the total observed decline in mortality from coronary heart disease in Auckland in 1981 among people under 70 years. If the Auckland patients with myocardial scores of 10 or more who had coronary artery bypass grafting were indeed similarly at risk to those patients from the United States in the 1960s, and their assumed annual mortality in the absence of operations was 12% each year, then an upper limit of the contribution of coronary artery bypass grafting to the decline would be 30%. As Rutherford noted, however, the annual mortality in the more recent Coronary Artery Surgery Study of medically treated patients with severe triple vessel disease was 2 1% compared with 11 4% in the 1960s.23 If the Auckland patients participated in this change in clinical course and thus their annual mortality in the absence of surgery was closer to 7% each year (instead of 12%) the contribution of coronary artery bypass grafting to the decline in mortality falls to 18%.
The lowest predictions of effect come from the European Coronary Surgery Study.26 The European study has the advantage of being a randomised trial, but it was limited to patients with stable chronic angina who did not require operations to relieve symptoms. If it is assumed that the Auckland patients with myocardial scores of 10 or more experienced only the same benefit as all patients in the European study the net gain from surgery in 1981 compared with 1974 would be seven deaths averted. This would account for 5% of the observed decline in mortality from coronary heart disease in Auckland.
TREATMENT OF HYPERTENSION
It is difficult to assess the contribution of improvements in the effectiveness of the treatment of hypertension in the community to the decline in mortality from coronary heart disease. In 1981 about 20% of the Auckland population aged 35-64 years were hypertensive, and 55% of these people were receiving pharmacological treatment.2 The state in Auckland in 1974 is unknown. In two studies in other parts of New Zealand in the early 1970s, however, the prevalence of hypertension was similar to that observed in 1981, but only 30% of hypertensive subjects received treatment. 28 
or 12% of the decline in mortality from coronary heart disease.
Discussion
These data suggest that medical management was responsible for about 40% of the observed decline in coronary heart disease that occurred in Auckland in 1981 (table) . The major contributions came from resuscitation before admission to hospital (16%) and the improved control ofhypertension (12%), with smaller contributions from coronary surgery, coronary units, and the use of beta blockers after myocardial infarction. It was not possible to assess the contribution of other aspects of medical care, such as stopping smoking and early mobilisation after myocardial infarction, though their contribution is probably small.
These figures are only estimates. The contribution of resuscitation before admission to hospital may have been underestimated as it is assumed that the original life support unit was operating in 1974 as efficiently as the units in 1981. The contribution ofimprovements in the control of hypertension was difficult to estimate, and the link between control of hypertension and reduction in mortality from coronary heart disease remains unclear. These results suggest that resuscitation before admission to hospital could continue to make an important contribution to reduction in mortality, as could improvements in the community effectiveness of the treatment of hypertension. The other medical interventions are unlikely to have much impact on mortality in the future. In Auckland 95% of patients with myocardial infarction are treated in hospital, over 90% of them receiving initial management in coronary care units.'3 Was the mortality one year after resuscitation in coronary care units to decrease to 15% this would avert only one more death from coronary heart disease in Auckland each year. Increased use of beta blockers after myocardial infarction would probably add little: if the percentage use in Auckland in 1981 had been 70% (instead of 30%) there would have been an extra six survivors. As Rose reasoned, the use of beta blockers will not make a noticeable contribution to national mortality trends.2 Likewise, given the already low mortality after infarction, the newer secondary preventive measures, such as coronary angioplasty and thrombolytic treatment, will not substantially influence future mortalities. Finally, given the continuing developments in medical treatment, the contribution of coronary artery surgery to future mortality trends will probably be small.
Most of the decline in mortality from coronary heart disease in Auckland during the period 1974-81 is attributable to factors other than specific medical interventions. There have been recent improvements in the national diet and a reduction in the consumption of tobacco, and these factors, or others not identified or unforseen at present, seem to be of major importance in New Zealand as in the United States.'
